Immune Response Protein Radiology Research 
The Pharma Data
MAY 16, 2021
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.
The Pharma Data
DECEMBER 23, 2020
Researchers say, however, they have never seen a virus acquire more than a dozen mutations at once. Of the 17 mutations, eight are in the gene that encodes the spike protein. One is N501Y, which has been previously shown to increase how the spike protein binds to the ACE2 receptor. In research in South Africa in B.1.1.7,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 23, 2020
Cellular (T cell) response were observed to multiple regions of the spike protein including the RBD region. 74% had measurable cellular responses at the 1.0 mg dose group demonstrated cellular responses. The 1.0 mg and 2.0 mg dose group and 84% demonstrating neutralizing antibodies in the 2.0
The Pharma Data
MARCH 25, 2022
Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. W911QY-21-9-0001.
Drug Discovery World
APRIL 14, 2023
The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.
The Pharma Data
AUGUST 22, 2021
More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. W911QY-21-9-0001. Increased resistance of SARS-CoV-2 variant P.1 Dong J, et al.
XTalks
SEPTEMBER 14, 2020
The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus. Drugs and Vaccines.
Expert insights. Personalized for you.
52 
Let's personalize your content